SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
June 26, 1997
Mallinckrodt Inc.
(Exact name of registrant as specified in its charter)
New York 1-483 36-1263901
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
7733 Forsyth Boulevard, St. Louis, MO 63105-1820
(Address of principal executive offices) (ZIP Code)
Registrant's telephone number, (314) 854-5200
including area code
<PAGE>
Item 5. Other Events
A press release was issued June 26, 1997. The relevant portion of
the text of that release was as follows:
MALLINCKRODT SECURES FDA CLEARANCE TO SUPPLY U. S. CUSTOMERS WITH
MOLYBDENUM FROM NETHERLANDS FACILITY
ST. LOUIS, Mo., June 26, 1997 - Mallinckrodt Inc. (NYSE:MKG) has
received clearance from the U. S. Food and Drug Administration to
supply U.S. customers with molybdenum (Mo-99) manufactured at its
facility in Petten, The Netherlands. Molybdenum is a metallic
element used to produce technetium (Tc-99m), which is considered the
workhorse of nuclear medicine and is a key component in medical
imaging diagnoses performed daily in hospitals throughout the world.
Millions of these procedures are performed each year.
"Almost a decade ago, Mallinckrodt initiated significant capital
investment in production facilities that would minimize our
customers' risk from shortages of molybdenum," said David Morra,
president of Mallinckrodt's Nuclear Medicine Division. "We're
extremely pleased with the FDA's decision because these
radiopharmaceutical products are used daily by our customers to
provide critical diagnostic services to patients worldwide."
FDA clearance became effective June 18. Morra said that limited
production has already begun at the Petten facility and will be
scaled up during the next several months, making it possible for
Mallinckrodt to supply U.S. customers with product from that
facility.
Mallinckrodt manufactures molybdenum for technetium generators,
which hospitals use to create single doses of radiopharmaceuticals on
site. By passing saline solution through Mallinckrodt's generator, a
shielded glass column containing molybdenum and technetium,
physicians can have radiopharmaceuticals at their disposal at any
time.
"With this approval, we can now supply all our needs for this
urgent material for the foreseeable future," Morra said. "There also
is a significant cost benefit for the company since we will no longer
need to purchase molybdenum from other suppliers."
Mallinckrodt Inc. is a major producer of diagnostic imaging
agents, medical devices, pain relief pharmaceuticals, catalysts and
laboratory and microelectronic chemicals. Serving healthcare and
specialty chemical markets worldwide, the St. Louis, Missouri-based
company, with fiscal 1996 adjusted net sales of $1.75 billion, sells
more than 1,000 products in more than 100 countries. The
Mallinckrodt web site address is (www.mallinckrodt.com).
# # #
Mallinckrodt Inc.
ROGER A. KELLER
Vice President, Secretary
and General Counsel
DATE: June 26, 1997
